Loading...
XSHE
300519
Market cap287mUSD
Jul 10, Last price  
12.49CNY
1D
2.63%
1Q
-19.26%
Jan 2017
-69.16%
IPO
29.23%
Name

Zhejiang Xinguang Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300519 chart
P/E
36.86
P/S
7.53
EPS
0.34
Div Yield, %
2.47%
Shrs. gr., 5y
-0.19%
Rev. gr., 5y
-3.73%
Revenues
265m
-0.86%
229,617,378249,854,530267,937,987292,109,437311,478,232315,313,657310,865,112276,257,364291,262,099283,080,270320,876,074320,876,074351,488,810351,488,810270,399,836267,659,926265,359,823
Net income
54m
+7.58%
46,854,08956,837,67372,468,959105,651,550118,784,216118,958,798106,159,24987,995,76893,900,71098,976,354114,280,359114,280,364108,821,010108,821,01264,356,48350,389,99454,211,458
CFO
69m
+28.99%
053,932,15557,511,46699,820,100124,840,438121,184,880124,232,04992,772,34798,266,202112,611,669142,355,309126,429,39753,290,42553,434,05268,924,494
Dividend
May 28, 20250.3 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Xinguang Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, chemical medicines, and health food in China. It offers pharmaceutical products that cover respiratory, digestive, and urinary systems, as well as cardiovascular, cerebrovascular, trauma, and pediatric diseases. The company was incorporated in 1998 and is headquartered in Shengzhou, China.
URL
IPO date
Jun 24, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT